Golimumab

Mechanism :

Human monoclonal antibody that binds to human tumor necrosis factor alpha (TNFa), thereby interfering with endogenous TNFa activity.

Indication :

• Psoriatic arthritis
• Polyarticular Juvenile Idiopathic arthritis
• Ulcerative colitis

Contraindications :

Hypersensitivity to golimumab, latex, or any other component of formulation or packaging; patients with severe infections (e.g., sepsis, tuberculosis, opportunistic infections); moderate or severe heart failure (NYHA class III/IV).

Dosing :

Adverse Effect :

Injections site reaction, viral infections, Positive ANA titre, increased AST/ALT, dizziness, paresthesia.

Interaction :

Abatacept, Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect. An increased risk of serious infection during concomitant use has been reported.
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide.
Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased.
Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.
Vaccines (Live): Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.

Hepatic Dose :